NCT02868541 (EMIRATH) is a clinical trial of Naso pharyngeal swab in Acute Respiratory Infection, sponsored by Assistance Publique Hopitaux De Marseille.

Who is sponsoring NCT02868541?

NCT02868541 is sponsored by Assistance Publique Hopitaux De Marseille.

What drugs are being tested in NCT02868541?

Interventions in NCT02868541: Naso pharyngeal swab.

What condition does NCT02868541 study?

NCT02868541 studies Acute Respiratory Infection.

Is NCT02868541 still recruiting?

NCT02868541 is currently completed. Last updated 28 October 2022.

Last reviewed 2022-10-28 · How we verify

NCT02868541: EMIRATH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessment of Pharyngeal Carriage of Microorganisms Responsible for Transmissible Acute Respiratory Infections in HAJJ Pilgrims.

Completed Last updated 28 October 2022

What this trial tests

trial testing Naso pharyngeal swab in Acute Respiratory Infection in 905 participants. Completed in 6 September 2019.

Timeline

25 January 2017

Primary endpoint
6 September 2019

6 September 2019

Quick facts

Lead sponsor	Assistance Publique Hopitaux De Marseille
Status	Completed
Study type	OBSERVATIONAL
Enrollment	905
Start date	25 January 2017
Primary completion	6 September 2019
Estimated completion	6 September 2019
Sites	1 location across France

Drugs / interventions tested

Naso pharyngeal swab

Conditions studied

Acute Respiratory Infection — all drugs for Acute Respiratory Infection →

Sponsor

Assistance Publique Hopitaux De Marseille — full company profile →

Who can join

18 and older, any sex, with Acute Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this project is to study the prevalence of viruses and bacteria responsible for transmissible acute respiratory infections in the respiratory tract of pilgrims returning from the trip. The patients included, will be the consultant pilgrims to the traveler health center, and before leaving for Hajj. Based on the results obtained in previous studies, it is estimated that 200 pilgrims will be included each year, 600 in total (inclusion period of 3 years). Respiratory secretions are then collected by nasal swab and throat (swab) prior to departure for the hajj. In return, patients will be reconvened systematic consultation to record medical events potentially encountered during the trip, and it will again be performed the same nasal swabs and throat. It will then be performed on these samples' return from hajj "molecular detection (PCR and RT-PCR) of 35 viruses and bacteria respiratory tropism: influenza (3), RSV (2), metapneumovirus (1), Coronavirus (4), Parainfluenzavirus (4), enteroviruses (4), rhinovirus (1), adenovirus (6) bocavirus, polyomavirus (2), pneumococcus, Bordetella pertussis, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Haemophilus influenzae, Neisseria meningitidis and Coxiella burnetii. Samples "return of hajj" positive should be cultured for the isolation of the strain. For patients positive return, it will be done further research of these 35 viruses and bacteria on samples "start of hajj," the same method described above. In addition to this systematic consultation, and if symptoms return, the pilgrims will be seen in consultation for a diagnosis evaluation and therapeutic management. This study will shed light on the acquisition of microorganisms respiratory tropism during the stay and on the potential risks associated with the circulation of these pathogens after the trip.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Respiratory Infection

Currently open trials in the same condition.

NCT06271655 — Rapid Diagnosis of Viral Acute Respiratory Infection to Decrease Unnecessary Antibiotic Utilization in the Emergency Dep · NA · active not recruiting
NCT06379542 — Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections · Phase 3 · recruiting
NCT05814237 — POS-ARI-ER Observational Study of Acute Respiratory Infections · recruiting
NCT04099082 — Signature of the Host Response to a Respiratory Viral Infection, in the Prediction of Bronchiolitis Obliterans · recruiting

Other Assistance Publique Hopitaux De Marseille trials

Trials by the same sponsor.

NCT07521644 — Dysbiosis of Methanogenic Archaea and Nanoarchaea in the Oral Microbiome · NA · not yet recruiting
NCT07357025 — Resting-State fMRI Study of Functional Connectivity After Gamma Knife Radiosurgery in Trigeminal Neuralgia · NA · not yet recruiting
NCT07356661 — Evaluation of the Efficacy of Neurofeedback Technique Based on EEG Desynchronization in Epileptic Patients · NA · not yet recruiting
NCT07399327 — Biomarkers of Response to SEEG Thermocoagulation · NA · not yet recruiting
NCT06999499 — Development of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02868541 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique Hopitaux De Marseille
Last refreshed: 28 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02868541.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing